Rheumatology International

RHEUMATOLOGY INTERNATIONAL is an independent journal reflecting world-wide progress in the research, diagnosis and treatment of the various rheumatic diseases. It is designed to serve researchers and clinicians in the field of rheumatology.

RHEUMATOLOGY INTERNATIONAL will cover all modern trends in clinical research as well as in the management of rheumatic diseases. Special emphasis will be given to public health issues related to rheumatic diseases, applying rheumatology research to clinical practice, epidemiology of rheumatic diseases, diagnostic tests for rheumatic diseases, patient reported outcomes (PROs) in rheumatology and evidence on education of rheumatology. Contributions to these topics will appear in the form of original publications, short communications, editorials, and reviews. "Letters to the editor" will be welcome as an enhancement to discussion. Basic science research, including in vitro or animal studies, is discouraged to submit, as we will only review studies on humans with an epidemological or clinical perspective. Case reports without a proper review of the literatura (Case-based Reviews) will not be published. Every effort will be made to ensure speed of publication while maintaining a high standard of contents and production.

Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.

《风湿病学国际》是一本独立杂志，反映全球各种风湿病研究、诊断和治疗的进展。它旨在为风湿病学领域的研究人员和临床医生服务。

《风湿病学国际》将涵盖临床研究以及风湿病管理的所有现代趋势。将特别强调与风湿病相关的公共卫生问题、将风湿病研究应用于临床实践、风湿病流行病学、风湿病诊断测试、风湿病患者报告结果 (PRO) 以及风湿病教育证据。这些主题的贡献将以原始出版物、简短通讯、社论和评论的形式出现。欢迎“致编辑的信”，以增强讨论。我们不鼓励提交基础科学研究，包括体外或动物研究，因为我们只会从流行病学或临床的角度审查人类研究。未经适当文献审查的病例报告（基于病例的审查）将不予发表。我们将尽一切努力确保出版速度，同时保持高标准的内容和制作。

提交出版的手稿必须包含一份声明，说明所有人类研究均已由适当的伦理委员会审查，因此已按照 1964 年《赫尔辛基宣言》适当版本规定的道德标准进行。文中还应明确说明，所有人在参与研究之前均已知情同意。应省略可能泄露研究对象身份的细节。

该刊已被国际权威数据库SCIE收录，该刊致力于发表经过严格同行评审的高质量原创文章，反映医学-风湿病学领域的新进展、新技术、新成果，促进该领域科研交流和科研成果转化。该刊2023年影响因子为3.2，平均审稿速度为 约16.月 ，近四年来没有被列入预警名单。如果您需要投稿发表服务及指导，可以联系我们的客服老师，我们专业专注服务期刊投稿协助10年，为您提供期刊投稿个性化定制服务，并且我们确保严格保密您的个人信息及稿件内容。